Unknown

Dataset Information

0

Intravenous injection of apolipoprotein A-V reconstituted high-density lipoprotein decreases hypertriglyceridemia in apoav-/- mice and requires glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1.


ABSTRACT: Apolipoprotein A-V (apoA-V), a minor protein associated with lipoproteins, has a major effect on triacylglycerol (TG) metabolism. We investigated whether apoA-V complexed with phospholipid in the form of a reconstituted high-density lipoprotein (rHDL) has potential utility as a therapeutic agent for treatment of hypertriglyceridemia (HTG) when delivered intravenously.Intravenous injection studies were performed in genetically engineered mouse models of severe HTG, including apoav-/- and gpihbp1-/- mice. Administration of apoA-V rHDL to hypertriglyceridemic apoav-/- mice resulted in a 60% reduction in plasma TG concentration after 4 hours. This decline can be attributed to enhanced catabolism/clearance of very-low-density lipoprotein (VLDL), where VLDL TG and cholesterol were reduced ?60%. ApoA-V that associated with VLDL after injection was also rapidly cleared. Site-specific mutations in the heparin-binding region of apoA-V (amino acids 186 to 227) attenuated apoA-V rHDL TG-lowering activity by 50%, suggesting that this sequence element is required for optimal TG-lowering activity in vivo. Unlike apoav-/- mice, injection of apoA-V rHDL into gpihbp1-/- mice had no effect on plasma TG levels, and apoA-V remained associated with plasma VLDL.Intravenously injected apoA-V rHDL significantly lowers plasma TG in an apoA-V deficient mouse model. Its intravenous administration may have therapeutic benefit in human subjects with severe HTG, especially in cases involving apoA-V variants associated with HTG.

SUBMITTER: Shu X 

PROVIDER: S-EPMC2988087 | biostudies-literature | 2010 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Intravenous injection of apolipoprotein A-V reconstituted high-density lipoprotein decreases hypertriglyceridemia in apoav-/- mice and requires glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1.

Shu Xiao X   Nelbach Lisa L   Weinstein Michael M MM   Burgess Braydon L BL   Beckstead Jennifer A JA   Young Stephen G SG   Ryan Robert O RO   Forte Trudy M TM  

Arteriosclerosis, thrombosis, and vascular biology 20101021 12


<h4>Objective</h4>Apolipoprotein A-V (apoA-V), a minor protein associated with lipoproteins, has a major effect on triacylglycerol (TG) metabolism. We investigated whether apoA-V complexed with phospholipid in the form of a reconstituted high-density lipoprotein (rHDL) has potential utility as a therapeutic agent for treatment of hypertriglyceridemia (HTG) when delivered intravenously.<h4>Methods and results</h4>Intravenous injection studies were performed in genetically engineered mouse models  ...[more]

Similar Datasets

| S-EPMC10512915 | biostudies-literature
| S-EPMC1218936 | biostudies-other
| S-EPMC2681406 | biostudies-literature
| S-EPMC11010956 | biostudies-literature
| S-EPMC1913910 | biostudies-literature
| S-EPMC3906832 | biostudies-literature
| S-EPMC3197940 | biostudies-literature
| S-EPMC3940157 | biostudies-other
| S-EPMC5708192 | biostudies-literature
| S-EPMC3153990 | biostudies-literature